drugset / Trial / NCT03799094
Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations
RandomizedParallel-groupSingle-blindTreatment
Summary
This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC patients.
Timeline
- Start
- 2018-12-05
- Primary completion
- 2020-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin C | Other / unclassified | 30 g | Intravenous |
| Background | Erlotinib | Small molecule | 150 mg | — |
| Background | Gefitinib | Small molecule | 0.25 g | — |
| Background | Osimertinib | Small molecule | 80 mg | — |